Alignment Healthcare, Inc.
NASDAQ:ALHC · NASDAQ Global Select
+$0.48 today
Vol 6.64M · Avg 5.33M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ALHC · Revenue to Net Income
Key Ratios
Analysis
$4.3B of revenue converted into $19.8M of net income for the selected period. Gross margin is 12.4% and net margin is 0.4%, showing how much revenue survives after costs and taxes. EPS is $0.09, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.9B +46.1% | $2.7B +48.3% | $1.8B +27.2% | $1.4B +22.8% | $1.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.5B +43.8% | $2.4B +48.3% | $1.6B +29.8% | $1.2B +20.3% | $1.0B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $488.6M +64.7% | $296.7M +47.6% | $201.0M +9.1% | $184.3M +43.2% | $128.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 12.4% +1.4pp | 11.0% -0.0pp | 11.0% -1.8pp | 12.8% +1.8pp | 11.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $0 -100.0% | $371.4M +20.8% | $307.4M +4.0% | $295.6M +1.6% | $291.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $473.8M +19.0% | $398.2M +21.1% | $328.8M +5.1% | $312.9M +2.0% | $306.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $30.5M +12.6% | $27.1M +24.9% | $21.7M +23.9% | $17.5M +9.1% | $16.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $45.3M +158.5% | -$77.4M +26.5% | -$105.3M +7.2% | -$113.5M +29.8% | -$161.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 1.1% +4.0pp | -2.9% +2.9pp | -5.8% +2.1pp | -7.9% +5.9pp | -13.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $14.8M +114.5% | -$101.6M +20.5% | -$127.8M +0.6% | -$128.6M +27.8% | -$178.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 0.4% +4.1pp | -3.8% +3.3pp | -7.0% +2.0pp | -9.0% +6.3pp | -15.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $15.8M -32.9% | $23.5M +10.9% | $21.2M +16.1% | $18.3M +4.9% | $17.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$15.7M +40.7% | -$26.5M -30.0% | -$20.4M +1.4% | -$20.7M -20.0% | -$17.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$958.0K +99.3% | -$128.1M +13.6% | -$148.2M +0.7% | -$149.3M +23.5% | -$195.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -0.0% +4.7pp | -4.7% +3.4pp | -8.1% +2.3pp | -10.4% +6.3pp | -16.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $20.0K -4.8% | $21.0K +195.5% | -$22.0K -106.5% | $339.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$724.0K +99.4% | -$128.0M +13.5% | -$148.0M +1.0% | -$149.5M +23.4% | -$195.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -0.0% +4.7pp | -4.7% +3.4pp | -8.1% +2.3pp | -10.4% +6.3pp | -16.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +99.4% | -$1 +15.2% | -$1 +4.8% | -$1 +27.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +99.4% | -$1 +15.2% | -$1 +4.8% | -$1 +27.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $198.0M +3.8% | $190.8M +2.5% | $186.2M +2.8% | $181.2M +5.4% | $172.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $198.0M +3.8% | $190.8M +2.5% | $186.2M +2.8% | $181.2M +5.4% | $172.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Oscar Health, Inc.
NYSE:OSCR
$7.25B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.45B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$5.29B
Envista Holdings Corp
NYSE:NVST
$4.19B
ICU Medical, Inc.
NASDAQ:ICUI
$3.45B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.25B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.97B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.70B
GRAIL, Inc.
NASDAQ:GRAL
$2.68B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ALHC generate?
Alignment Healthcare, Inc. (ALHC) reported $3.95B of revenue in fiscal 2025.
Is ALHC profitable?
Alignment Healthcare, Inc. (ALHC) reported -$724,000.00 of net income, with a net margin of -0.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.